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AbstrAct
Objective We compared the physician-assessed 
diagnostic likelihood of SLE resulting from standard 
diagnosis laboratory testing (SDLT) to that resulting 
from multianalyte assay panel (MAP) with cell-bound 
complement activation products (MAP/CB-CAPs), which 
reports a two-tiered index test result having 80% 
sensitivity and 86% specificity for SLE.
Methods Patients (n=145) with a history of positive 
antinuclear antibody status were evaluated clinically 
by rheumatologists and randomised to SDLT arm (tests 
ordered at the discretion of the rheumatologists) or to 
MAP/CB-CAPs testing arm. The primary endpoint was 
based on the change in the physician likelihood of SLE on 
a five-point Likert scale collected before and after testing. 
Changes in pharmacological treatment based on laboratory 
results were assessed in both arms. Statistical analysis 
consisted of Wilcoxon and Fisher’s exact tests.
Results At enrolment, patients randomised to SDLT 
(n=73, age=48±2 years, 94% females) and MAP/CB-
CAPs testing arms (n=72, 50±2 years, 93% females) 
presented with similar pretest likelihood of SLE (1.42±0.06 
vs 1.46±0.06 points, respectively; p=0.68). Post-test 
likelihood of SLE resulting from randomisation in the MAP/
CB-CAPs testing arm was significantly lower than that 
resulting from randomisation to SDLT arm on review of 
test results (−0.44±0.10 points vs −0.19±0.07 points) 
and at the 12-week follow-up visit (−0.61±0.10 points vs 
−0.31±0.10 points) (p<0.05). Among patients randomised 
to the MAP/CB-CAPs testing arm, two-tiered positive test 
results associated significantly with initiation of prednisone 
(p=0.034).
Conclusion Our data suggest that MAP/CB-CAPs 
testing has clinical utility in facilitating SLE diagnosis and 
treatment decisions.
IntROduCtIOn
SLE remains one of the most challenging auto-
immune rheumatic diseases to diagnose in 
rheumatology practice and is a leading cause 
of death in young females.1 The difficulties in 
the ability of healthcare providers to make a 
diagnosis of SLE is primarily related to the low 
prevalence of the disease and the heteroge-
neity of symptoms that are often non-specific 
and overlapping with many other conditions 
such as fibromyalgia.2 Diagnostic challenges 
are also due in part to the lack of diagnostic 
criteria and limitations with current diagnostic 
immunology testing, primarily antinuclear 
(ANA) and anti-double stranded (ds) DNA 
antibodies that lack specificity and sensitivity, 
respectively.3 It follows that the validation and 
introduction in clinical practice of novel SLE 
markers or testing methods that facilitate the 
diagnosis of the disease is an unmet need for 
the rheumatologists. Early diagnosis can iden-
tify patients likely to benefit from treatment 
(such as hydroxychloroquine (HCQ)) to limit 
organ damage and decrease healthcare utili-
sation.4 In addition, accurate determination 
of the unlikely SLE diagnosis in ANA-positive 
patients with non-specific symptoms is impor-
tant and can have direct benefit by decreasing 
inappropriate referrals to the rheumatologist.
Complement hyperconsumption due to acti-
vation of the complement system is intimately 
associated with SLE and measurement of 
serum complement levels is now integrated in 
modern classification criteria for the disease.5 
Over the past two decades, many studies have 
reported that quantification of cell-bound 
complement activation products (CB-CAPs) 
is a valid measure of classical complement 
pathway activation and has demonstrated 
value in SLE diagnosis and monitoring.3 6 A 
multianalyte assay panel (MAP) that combines 
CB-CAPs (C4d on erythrocytes (EC4d) and B 
cells (BC4d)) with eight autoantibodies has 
been developed to assist rheumatologists with 
the differential diagnosis of SLE6 and multiple 
studies support the clinical validity and 
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accuracy of the panel in distinguishing SLE from a variety 
of other rheumatic diseases.3 7–10 Furthermore, MAP and 
CB-CAPs consistently outperform serum complement 
levels for SLE diagnosis. A case–control, retrospective 
review of medical charts also suggested the clinical utility 
of MAP/CB-CAPs laboratory testing in assisting rheuma-
tologists in real-world practice.11 However, prospective 
data comparing standard diagnosis laboratory testing 
(SDLT) to MAP/CB-CAPs laboratory testing is lacking. In 
this randomised study, our objective was to assess prospec-
tively the clinical utility of diagnostic immunology testing 
and MAP/CB-CAPs in assisting rheumatologists with the 
diagnosis of SLE. We also evaluated whether treatment 
decisions were affected by the treatment arms to which 
the patients/physicians were assigned.
MethOds
The Clinical Laboratory Assessment and Recommen-
dation for Lupus (CARE for Lupus) was a multicen-
tred, randomised and prospective study in the USA 
that enrolled patients referred to board-certified rheu-
matologists with a suspicion of SLE. Patient consent 
was collected for all patients. At enrolment, all patients 
presented with a history of ANA positivity within the 
prior 6 months and were assessed clinically within 
3 months of their referral to rheumatologists. Patients 
were randomised to two different groups (1:1) on the 
day of enrolment using block randomisation of 20 
patients. For the SDLT group, no recommendation was 
made to the rheumatologists with regard of which labo-
ratory tests to order and what laboratory to order them 
from. The other randomisation group corresponded to 
the MAP/CB-CAPs laboratory testing method. Both the 
sponsor and investigators were blinded to the randomi-
sation list for the duration of the study. MAP/CB-CAPs 
combines CB-CAPs (erythrocyte bound C4d (EC4d) and 
B-lymphocyte bound C4d (BC4d)) with eight autoanti-
bodies (ANA, anti-Smith, anti-dsDNA (confirmed using 
Crithidia indirect immunofluorescence (IIF)), anticyclic 
citrullinated peptide (CCP), anti-centromere B (CENP), 
anti-Jo1, anti-Scl-70 and anti-SSB antibodies) to produce 
a two-tiered index value, in which a positive test result 
(>0 index value combining tier 1 and tier 2) results into 
80% sensitivity and 86% specificity in distinguishing SLE 
from a control group of patients with other autoimmune 
rheumatic diseases.3 Details about the two-tiered method 
is provided in the online supplementary figure 1. MAP/
CB-CAPs index value was measured at Exagen (Vista, 
California, USA), which runs a clinical laboratory accred-
ited by the College of American Pathologists as currently 
approved by the Clinical Laboratory Evaluation Program 
in the state of New York.6 For all patients, venous blood 
was collected at the time of clinical assessment and 
randomisation and was shipped overnight to Exagen in 
transportation kits. The MAP/CB-CAPs index value was 
reported to clinicians only for the patients randomised to 
the MAP/CB-CAPs testing arm. In addition to the index 
value, autoantibody levels were reported individually and 
were considered positive or negative based on the manu-
facturer cutoffs. EC4d and BC4d were also reported indi-
vidually as net mean fluorescent intensity (MFI) with 
abnormal levels above the 99th percentile of a normal 
healthy group (14 net MFI and 60 net MFI, respectively). 
ANA titre by indirect immunofluorescence (on NOVA 
View, Inova Diagnostics, San Diego, California, USA) was 
also reported. The MAP/CB-CAPs index score was meas-
ured also from blood of patients randomised to SDLT 
arm; however, clinicians remained blinded to test results 
for the duration of the study.
Marker results determined in the group of patients 
enrolled in the CARE study were compared with a data-
base of 283 754 specimens submitted to the clinical labo-
ratory for diagnosing SLE. All specimens collected for 
the study were processed with the daily clinical load and 
quality system management in place in the clinical labo-
ratory in accordance to standard operating procedures.
A five-point Likert scale (0: very low; 1: low; 2: moderate; 
3: high; 4: very high) estimating the physician likelihood 
for SLE was collected pretest and post-test. Per protocol, 
all patients presented with a low to moderate likelihood 
of SLE at enrolment (1 or 2 points on the Likert scale), 
and all cases were adjudicated by lupus experts (AW and 
EM) at the time of enrolment. An adjudicator deter-
mined whether there was agreement that the patient 
met the criteria for low or moderate likelihood of SLE 
based on clinical history, physical findings and any labo-
ratory testing prior to enrolment. In all cases when the 
first adjudicator disagreed with the investigator and in 
a subset of cases when the first adjudicator agreed with 
the investigator, a second adjudication was performed 
(blinded as to agreement or disagreement). If both adju-
dicators disagreed with the investigator (too high or too 
low likelihood of SLE), then the patient was considered a 
screen failure. Both adjudicators remained blinded as to 
group assignment and laboratory testing post-enrolment. 
During follow-up, the post-test likelihood of SLE was also 
collected using the five-point Likert scale and its change 
before and after testing (on review of test results and 12 
weeks after enrolment) was used to quantify clinical utility. 
Patient-reported outcomes measuring health-related 
quality of life using five-level EQ-5D (EQ-5D-5L version) 
was collected pretesting and post-testing at 12 weeks. 
Physician global assessment (PGA) of disease activity (0–3 
points scale) was collected at enrolment (pretesting) 
and at 12-week follow-up. Initiation of HCQ or predni-
sone pretesting and post-testing (on review of test results 
and 12 weeks after enrolment) was also collected for all 
subjects. All physician and patient-reported outcomes 
were collected using web-based interface and electronic 
data capture (ClinCapture, San Francisco, California, 
USA). Statistical analysis (using R) consisted of Wilcoxon, 
Kruskal Wallis, Fisher’s exact and linear mixed-effect 
models as appropriate.
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Table 1 Demographics at enrolment
SDLT arm
MAP/CB-CAPs 
testing arm
Number of patients 73 72
Age (years) 48.4±1.6 50.0±1.8
Gender (% females) 94.5% 93.1%
Ethnicities
Caucasians (%) 67.1% 73.6%
African Americans (%) 24.7% 18.1%
Asians (%) 2.7% 2.8%
Others (%) 5.5% 5.6%
Days since referral* 28±3 33±3
ANA (historical, %)† 100% 100%
PGA (0–3 point) 1.1±0.1 1.2±0.1
EQ5D-5L‡ 0.767±0.015 0.764±0.019
Likelihood of SLE (0–5 
points)
1.42±0.06 1.46±0.06
Prednisone (%) 5.5% 5.6%
Hydroxychloroquine (%) 9.6% 13.9%
Results are expressed as average (SEM) and percent as 
appropriate.
*Per protocol, all patients were referred to the rheumatologist for 
less than 3 months.
†Per protocol, all patients had ahistory of ANA positivity.
‡EQ5D-5L was available in 64 and 66 patients randomised to SDLT 
and MAP/CB-CAPs arm, respectively.
CB-CAP, cell-bound complement activation products; EQ5D-
5L, five-level EuroQol five-dimensional questionnaire; MAP, 
multianalyte assay panel; PGA, physician global assessment; 
SDLT, standard diagnosis laboratory testing.
Table 2 Physician-reported likelihood of SLE pretest and 
post-test
Pretest; 
enrolment
Post-test; review 
of test results
Post-
test;12 weeks
SDLT arm
n=73
1.42±0.06 1.23±0.08 
(−0.19±0.07)
1.11±0.10 
(−0.31±0.10)
MAP/CB-CAPs 
testing arm
n=72
1.46±0.06 1.01±0.10 
(−0.44±0.10)
0.85±0.10 
(−0.61±0.10)
Results are expressed as mean (SEM) at each study visit and as 
change from enrolment (in parenthesis).
CB-CAPs, cell-bound complement activation products; MAP, 
multianalyte assay panel; SDLT, standard diagnosis laboratory testing.
Results
Patients and laboratory results
A total of 145 subjects were enrolled at 32 sites between 
July 2017 and December 2018 and randomised to SDLT 
arm and MAP/CB-CAPs testing arm. Enrolment details are 
summarised in online supplementary figure 2. At enrol-
ment, pretest likelihood of SLE was similar in the SDLT 
and MAP/CB-CAPs testing arms (1.42±0.06 vs 1.46±0.06 
points, respectively; p=0.68). Patient demographics are 
summarised in table 1. Signs and symptoms at enrol-
ment in each of the randomisation group are presented 
in the online supplementary table 1. The components 
of the MAP/CB-CAPs panel in each group is presented 
in the online supplementary table 2; positivity rate was 
comparable across randomisation groups (p>0.50) and 
consistent with that of a population of patients tested 
in the clinical laboratory during a 6-year period (2012–
2018), except for ANA as determined by IIF (81% vs 60%; 
p<0.01). The positivity rate for the two-tiered index value 
was 12.5% in the MAP/CB-CAPs testing arm (2.7% tier 1 
positive and 9.8% tier 2 positive) and 15.1% in the SDLT 
arm (2.8% tier 1 positive and 12.3% tier 2 positive). Diag-
nostic immunology tests ordered in the group of patients 
randomised to SDLT arm are presented in online supple-
mentary table 3.
diagnosis
On review of test results, there was a significant decrease 
in post-test likelihood of SLE, irrespective of randomi-
sation arm (Wilcoxon paired test; p<0.01). Results are 
presented in table 2. Post-test likelihood of SLE resulting 
from randomisation to the MAP/CB-CAPs testing arm 
was lower than that resulting from randomisation to 
the SDLT arm (−0.44±0.10 points vs −0.19±0.07 points, 
respectively; p=0.027) and this significant impact on 
decreasing the likelihood of SLE remained signifi-
cant at the 12-week follow-up visit (−0.61±0.10 points vs 
−0.31±0.10 points, respectively; p=0.025). At the 12-week 
visit, a significant greater decrease in the likelihood of 
SLE (decrease ≥1 point from enrolment) was observed 
in the group of patients randomised to MAP/CB-CAPs 
testing arm (40/72, 56%) when compared with the SDLT 
arm (27/73, 37%) (difference=19%; p=0.031). Figure 1 
highlights the change in likelihood of SLE post-test by 
two-tiered index score. As expected, in the group of 
patients randomised to the MAP/CB-CAPs arm, a posi-
tive two-tiered test score associated with higher post-test 
likelihood of SLE (p=0.008), in contrast to the group of 
patients randomised to the SDLT arm (blinded to MAP/
CB-CAPs test results; p=0.271).
Overall, among patients negative for MAP/CB-CAPs 
test results (125 subjects), a lower likelihood of SLE 
(decrease ≥1 point from enrolment) was detectable at 
12 weeks in the group of patients randomised to MAP/
CB-CAPs testing arm (38/63, 60%) when compared with 
the SDLT arm (23/62, 37%) (difference=23%) (p=0.012). 
None of the patients randomised to the MAP/CB-CAPs 
testing arm presented with higher post-test likelihood of 
SLE in the presence of negative test results. Conversely, 
among patients positive for MAP/CB-CAPs (20 subjects), 
a higher likelihood of SLE (increase ≥1 point from 
enrolment) was detectable at 12 weeks (4/9, 44%) in 
patients randomised to the MAP/CB-CAPs testing arm 
when compared with the SDLT arm (1/11, 9%) (differ-
ence=35%; p=0.127). Results are presented in the online 
supplementary table 4. Linear mixed-effect models also 
revealed that the post-test likelihood of SLE decreased in 
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Figure 1 Change in SLE likelihood from enrolment to week 12 by two-tiered index test results The change in SLE likelihood 
pretest and post-test is indicated. (A) Multianalyte assay panel/cell-bound complement activation products (MAP/CB-CAPs) 
randomisation group; (B) standard diagnosis laboratory testing (SDLT) randomisation group. Kruskal-Wallis analysis of variance 
p values are provided for each group.
Table 3 Linear mixed-effect models of SLE likelihood 
in relation to testing arm and MAP/CB-CAPs test result 
(positive or negative).
Slope estimate 
(SEM) P value
Time from enrolment (per visit follow-
up)
−0.23±0.03 <0.001
Randomisation to MAP/CB-CAPs 
testing arm
−0.174±0.080 0.030
Positive MAP/CB-CAPs test results +0.311±0.116 0.008
CB-CAPs, cell-bound complement activation products; MAP, 
multianalyte assay panel.
SDLT (estimate: −0.16±0.04 per visit of follow-up; p<0.01) 
and MAP/CB-CAPs testing arms (estimate: −0.31±0.04 per 
visit of follow-up; p<0.01). Multivariate linear mixed-ef-
fect models established that post-test likelihood of SLE 
associated with randomisation to MAP/CB-CAPs testing 
arm and positive MAP/CB-CAPs test result after adjusting 
for follow-up period (table 3).
Other outcomes and treatment
At enrolment, patients presenting with a positive MAP/
CB-CAPs test result had higher PGA than those with 
negative MAP/CB-CAPs test result (1.44±0.14 (n=20) vs 
1.10±0.05 (n=125)) (p=0.030). At the 12-week follow-up, 
a greater improvement in PGA was observed in the MAP/
CB-CAPs testing arm (−0.39±0.08 (n=72)) when compared 
with the SDLT testing arm (−0.29±0.06 (n=73)) but the 
difference was not significant (p=0.39). Prednisone was 
started in 10% (7/73) patients randomised to SDLT arm 
versus 6% in patients randomised to the MAP/CB-CAPs 
(4/72) (p=0.53). HCQ was started in 25% (18/73) patients 
randomised to SDLT arm versus 14% (10/72) patients 
randomised to MAP/CB-CAPs testing arm (p=0.14). The 
impact of the laboratory testing on the initiation of pred-
nisone and HCQ in the group of patients randomised to 
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Figure 2 Initiation of prednisone and HCQ by two-tiered test results in MAP/CB-CAPs testing arm. Fisher’s exact p values 
comparing the three groups are are provided. Prednisone and HCQ were initiated in 22% and 33% patients testing positive 
for MAP/CB-CAPs (positive tier 1 or positive tier 2), respectively. CB-CAPs, cell-bound complement activation products; HCQ, 
hydroxychloroquine.
the MAP/CB-CAPs testing arm is presented in figure 2 
and revealed that the MAP/CB-CAPs test results associ-
ated significantly with initiation of prednisone (p=0.034) 
and a similar trend was observed with initiation of HCQ 
(p=0.112). The initiation of HCQ or prednisone by 
marker in the group of patients randomised in SDLT arm 
is presented in online supplementary table 5 and did not 
reach significance for any markers (p>0.13).
Finally, in the group of patients randomised to the 
MAP/CB-CAPs testing arm, a positive MAP/CB-CAPs 
test result associated with increased EQ5D-5L index 
score from enrolment to visit 2 (estimate: +0.054±0.024; 
p=0.028), and greater improvements were detectable 
when compared with the group of patients positive for 
the MAP/CB-CAPs test result and randomised to the 
SDLT arm (mean+0.099±0.046 (n=8) vs −0.008±0.050 
(n=8); p=0.049) (online supplementary table 6).
dIsCussIOn
This study is the first prospective multisite randomised 
study aimed to compare and quantify the clinical utility 
of different laboratory testing methods in facilitating the 
diagnosis of SLE. The clinical utility of antibody systems 
in the assessment of SLE is undisputed. Although these 
biomarkers are known to lack ideal diagnostic accuracy, 
rheumatologists have relied on them to facilitate the 
differential diagnosis of SLE. Therefore, it is recognised 
that new technologies that improve standard diagnostic 
laboratory and immunology testing in SLE are needed. 
However, the improvement in clinical validity and accu-
racy of novel diagnostic tests (over standard practice) 
on their own is insufficient to satisfy the scrutiny from 
stakeholders in the healthcare system, including payors, 
clinicians and patients.12 New technologies introduced in 
clinical laboratory practice must demonstrate their value 
in the real-life setting. We have previously established that 
MAP with CB-CAPs has clinical utility in rheumatologist 
practices, by retrospective chart review,11 using physi-
cian-reported likelihood of SLE for patients evaluated for 
signs and symptoms of SLE.
In this study, our objective was to establish the clin-
ical utility of the MAP/CB-CAPs in clinical practice in a 
prospective, scientific study. There were some challenges 
associated with the design of the study, especially due to 
the lack of consensus and heterogeneity regarding the 
SDLT in patients who are being considered for a diag-
nosis of SLE. Therefore, we purposely made no recom-
mendation as to what tests to order or what laboratory 
to order them from in the group of patients randomised 
to the SDLT arm, to better reflect common clinical prac-
tice. Clinical utility was defined probabilistically and 
semiquantitatively using the change in the likelihood 
of SLE, assessed using five-point Likert scale collected 
pretesting and post-testing. All patients enrolled in the 
study were referred with an history of ANA positivity and 
were considered to have a low to moderate likelihood of 
SLE as determined by the enrolling rheumatologists and 
the adjudicators, based on prior history and clinical and 
demographic features at presentation. Since the criteria 
for entry were a positive ANA and a low to moderate 
likelihood of SLE, it is not surprising that most of the 
patients enrolled in this study were negative for the MAP/
CB-CAPs index score in both arms. This is comparable 
to the target population of patients tested in our clinical 
laboratory. As expected, the likelihood of SLE decreased 
in the group of patients randomised to SDLT arm, and 
these data are consistent with the low prevalence of SLE 
in the population of ANA-positive patients referred to the 
rheumatologist for a suspicion of SLE.
The lower post-test likelihood of SLE in the group of 
patients randomised to the MAP/CB-CAPs arm compared 
with the SDLT arm was observed early on and was main-
tained at 12 weeks. Importantly, in the presence of MAP/
CB-CAPs negative test result, we detected a significantly 
lower likelihood of SLE in patients randomised to the 
MAP/CB-CAPs testing arm when compared with the 
SDLT arm, thereby indicating greater confidence that 
the diagnosis of SLE is unlikely with the MAP/CB-CAPs 
testing. Conversely, greater likelihood of SLE was detect-
able in the presence of a positive MAP/CB-CAPs test 
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result. Altogether, these data are consistent with the 
greater diagnostic accuracy of the MAP/CBCAPs panel 
and its ability to influence diagnostic decision-making.
We also collected treatment information and our data 
revealed that positive two-tiered MAP/CB-CAPs test 
results led to initiation of prednisone and HCQ treat-
ment, thus suggesting that the MAP/CB-CAPs test results 
in the context of clinical findings and symptoms were 
actionable and led to changes in physician’s behaviour 
pharmacological intervention in that group of patients. 
On clinical grounds, these patients were deemed to have 
low to moderate likelihood of SLE. Therefore, it is not 
surprising that a positive test result would increase their 
estimate of likelihood of SLE and thus initiation of appro-
priate treatment such as steroids or HCQ. In contrast, 
in the group of patients randomised to SDLT, no signif-
icant association between the markers and initiation of 
prednisone or HCQ was detected. There was also signif-
icant improvement in the quality of life in the group of 
patients randomised to the MAP/CB-CAPs treatment arm 
and given a positive test result, and we speculate that the 
laboratory information provided may have decreased the 
uncertainty of the diagnosis for the patient.
We acknowledge that there are potential limitations 
in our study. First, long-term impact on health status 
and patient outcome was not collected after 12 weeks. 
Second, the short time frame of the study did not allow us 
to collect long-term data, including fulfilment of the clas-
sification criteria for SLE or the impact of the diagnostic 
strategy on formal health outcome including healthcare 
utilisation. However, the improvement in the diagnostic 
certainty by rheumatologists with either a negative or posi-
tive MAP/CB-CAPs compared with SDLT, and the impact 
of the positive test results on the initiation of therapy and 
EQ-5D is likely to associate with changes in outcomes. In 
conclusion, in this first randomised, prospective, multi-
centre study, our data suggest the clinical utility of a new 
diagnostic intervention to aid community-based rheuma-
tologists and the challenging patients they manage.
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